Repros Therapeutics Inc. (RPRX) announced after the bell Wednesday that Androxal met both co-primary endpoints in its first pivotal study.
Repros Therapeutics gapped open dramatically higher Thursday, but traded in a range throughout the session. Shares finished with a gain of 6.97 at $16.10 on the highest volume of the year. The stock surged to a 2-month high and re-crossed both its 50 and 200-day moving averages.
For comments and feedback: editorial@rttnews.com